Project: A tailored and rational approach for treating cancer patients with a YAP-TEAD inhibitor
To deliver a first-in-class drug for the therapy of malignant mesothelioma, non-small cell lung cancer (NSCLC), triple-negative breast cancer and pediatric cancer, we will: Deliver a clinical development drug candidate blocking YAP-TEAD interaction Develop a companion biomarker for patient selection and drug efficacy based on - a genomic signature - YAP nuclear localization by immunohistochemistry Show preclinical efficacy as single agent or in combination with standard of care
Acronym | TheraYAP (Reference Number: 10483) |
Duration | 01/10/2016 - 01/07/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |